promoters in mammals. In these regions there is a high concentration of cytosineguanine pairs linked with phosphate bonds. These CpG sites are unmethylated when genes are expressed; hence their methylation in gene promoters may inhibit genic expression by inactivating the genes involved. Transcriptional inactivation by methylating CpG islands in tumor suppressor gene promoters is a relevant carcinogenesis mechanism, what is usually referred to as methylator phenotype. The mechanism through which methylation occurs in the promoter regions of various genes has been shown to play a role in a proportion of CRCs nearing 35% (6) . This is also designated the «serrated pathway to colorectal carcinogenesis», as it seemingly emerges from a serrated precursor lesion (whose histology may include hyperplastic polyps, sessile serrated polyps, and serrated adenomas). In contrast to microsatellite status screening, where Bethesda's panel is used by consensus (7), there is still no agreement on an optimal panel for CpG islands or sites regarding CIMP characterization.
A number of differentiating features may be identified in these tumors. Thus, they seem to prefer the proximal colon, female gender, and older age; poorly differentiated tumors are more common and, from a molecular viewpoint, there is a wider presence of BRAF mutations, whereas the mutation rate for TP53 is lower (8-10).
The mechanisms for CRCs emerging via this pathway seem to stem from a BRAF activating mutation, which inhibits physiological apoptosis at the level of epithelial cells in the colon. From this event serrated lesions may give rise to hyperplastic polyps or sessile serrated polyps. These lesions are susceptible to CpG island methylation in the promoter regions of multiple genes, hence they may induce epigenetic silencing -an initially random indirect inactivation of genes. Methylation of the MLH1 promoter, which is very common in these cases, would originate sporadic CRCs with MSI. In this respect the fact that most sporadic cases with MSI are CIMP positive should be highlighted, whereas the presence of this phenotype in Lynch syndrome patients is uncommon (11, 12) .
From a clinical standpoint the diagnostic, prognostic, and therapeutic implications of the CIMP pathway are under analysis today. Certain papers focus on the utility of methylated gene identification in plasma or fecal samples for the early diagnosis of CRC (13) (14) (15) (16) (17) (18) , even in an attempt to predict, from the mucosal wash fluid during colonoscopy, CRC cases with a higher degree of invasiveness at the colonic wall (19) . From a prognostic point of view a number of approaches have been essayed. On the one hand, trying to relate the methylation status of certain genes to outcome (for example, IGF2, which seems to suggest a poor prognosis) (20) . Another instance is the paper reported in this issue of Revista Española de Enfermedades Digestivas, by Vengazones et al. (21) , where the clinical and prognostic implications of p16 methylation in CRCs are discussed. Overall studies have also been undertaken to assess the prognosis of tumors with CIMP, which remains blurry given the bias of a common association with mutations in BRAF, suggestive of a poor prognosis on their own (22) . As can be surmised, also the various epigenetic forms of CRC have been studied regarding the sensitivity-resistance to chemotherapy, but little is known because most studies were performed in vitro, among other reasons (23) .
As pointed out above, the need to understand the molecular basis of CRC is of paramount importance to correctly design both diagnostic and therapeutic strategies. In this regard, CIMP screening is most relevant, even more so given it is the most recently identified carcinogenesis pathway, as is the screening for specific CpG
